# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001615774-19-002242
Filing Date
2019-02-11
Accepted
2019-02-11 16:10:51
Documents
4
Period of Report
2019-04-05
Effectiveness Date
2019-02-11

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | s115994_def14a.htm | DEF 14A | 507122
2 | GRAPHIC | s115994_img1.jpg | GRAPHIC | 322769
3 | GRAPHIC | s115994_proxy1.jpg | GRAPHIC | 272892
4 | GRAPHIC | s115994_proxy2.jpg | GRAPHIC | 305622
| Complete submission text file | 0001615774-19-002242.txt |  | 1749950

Mailing Address 51 W 52ND STREET, 7TH FLOOR NEW YORK NY 10019-6163
Business Address 51 W 52ND STREET, 7TH FLOOR NEW YORK NY 10019-6163 800-689-3939
ANAVEX LIFE SCIENCES CORP. (Filer) CIK: 0001314052 (see all company filings)

EIN.: 208365999 | State of Incorp.: NV | Fiscal Year End: 0930
Type: DEF 14A | Act: 34 | File No.: 001-37606 | Film No.: 19585497
SIC: 8731 Services-Commercial Physical & Biological Research